Cullinan Therapeutics (CGEM) Other Non-Current Assets (2020 - 2026)
Cullinan Therapeutics' (CGEM) quarterly Other Non-Current Assets came in at $297000.0 in Q1 2026, down 18.85% year-on-year from $366000.0 in Q1 2025, and little changed quarter-over-quarter from $297000.0 in Q4 2025.
Cullinan Therapeutics (CGEM) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Cullinan Therapeutics' Other Non-Current Assets history runs 7 years deep, the most recent figure standing at $297000.0 for Q1 2026.
- On a quarterly basis, Other Non-Current Assets fell 18.85% year-over-year to $297000.0 in Q1 2026; TTM through Mar 2026 was $297000.0, a 18.85% decrease from a year earlier, with the FY2025 full-year figure at $297000.0, down 18.85% from the prior year.
- Other Non-Current Assets steadied at $297000.0 in Q1 2026 per CGEM's latest filing, from $297000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $460000.0 in Q3 2022 and bottomed at $100000.0 in Q2 2022.
- The 5-year median for Other Non-Current Assets is $459000.0 (2022), against an average of $378588.2.
- Across the five-year window, Other Non-Current Assets slumped 31.97% in 2022 and soared 359.0% in 2023, its largest moves.
- Year by year, Other Non-Current Assets stood at $459000.0 in 2022, then changed by 0.0% to $459000.0 in 2023, then declined by 20.26% to $366000.0 in 2024, then declined by 18.85% to $297000.0 in 2025, then changed by 0.0% to $297000.0 in 2026.
- Per Business Quant, the three latest CGEM Other Non-Current Assets figures stand at $297000.0 (Q1 2026), $297000.0 (Q4 2025), and $361000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Cullinan Therapeutics | 368.65 Mn | 368.65 Mn | - | 297,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 297,000.00 |
| Dec 31, 2025 | 297,000.00 |
| Sep 30, 2025 | 361,000.00 |
| Jun 30, 2025 | 367,000.00 |
| Mar 31, 2025 | 366,000.00 |
| Dec 31, 2024 | 366,000.00 |
| Sep 30, 2024 | 460,000.00 |
| Jun 30, 2024 | 460,000.00 |
| Mar 31, 2024 | 460,000.00 |
| Dec 31, 2023 | 459,000.00 |
| Sep 30, 2023 | 459,000.00 |
| Jun 30, 2023 | 459,000.00 |
| Mar 31, 2023 | 459,000.00 |
| Dec 31, 2022 | 459,000.00 |
| Sep 30, 2022 | 460,000.00 |
| Jun 30, 2022 | 100,000.00 |
| Mar 31, 2022 | 147,000.00 |
| Dec 31, 2021 | 147,000.00 |
| Sep 30, 2021 | 147,000.00 |
| Jun 30, 2021 | 147,000.00 |